Revance models smiling

Inspiring individuals across generations

Our portfolio of science-powered products in aesthetics, skincare, and therapeutics drives innovation beyond convention to offer care for individuals across the generations.

Revance Aesthetics model smiling

Aesthetics

At Revance Aesthetics, we believe science enhances beauty. From dynamic facial movement in fillers to a peptide-formulated neuromodulator, our award-winning injectable products are one of a kind.¹¯⁷ From the #1 microneedling device in the US to a unique microbe technology, we offer industry-leading products.⁸ All to inspire a beautiful confidence through science.

Aesthetics
Revance Consumer Skincare model smiling

Consumer Skincare

With a long heritage in skincare, we're committed to skin science and empowering optimal self-care. From the #1 selling mineral sunscreen brand to a groundbreaking skin barrier strengthening formula, our products treat a range of skincare concerns, from acne to sun protection to aging—helping people feel confident in their own skin at any age.9

Consumer skincare
Revance Therapeutics model smiling

Therapeutics

Revance is advancing treatments for movement disorders with DAXXIFY® (daxibotulinumtoxinA-lanm) for injection, a peptide stabilized botulinum toxin. This novel formulation is designed to deliver consistent clinical outcomes and sustained symptom control―addressing a significant unmet need in cervical dystonia and beyond. As our therapeutic portfolio expands, Revance remains focused on evidence-based innovation, clinical excellence, and scalable growth to create enduring value.

Therapeutics

Other Products

Learn about our platelet rich plasma system.

ProGen PRP® Eclipse Logo Learn More

References

  1. RHA® Directions for Use. Geneva, Switzerland: Teoxane SA.
  2. DAXXIFY®. Prescribing Information. Revance Therapeutics, Inc; 2023.
  3. BOTOX® Cosmetic. Prescribing Information. Allergan Inc; 2023.
  4. XEOMIN®. Prescribing Information. Merz Pharmaceuticals GmbH; 2024.
  5. DYSPORT®. Prescribing Information. Ipsen Biopharmaceuticals, Ltd; 2023.
  6. JEUVEAU®. Prescribing Information. Evolus, Inc; 2020.
  7. LETYBO®. Prescribing Information. Hugel, Inc; 2024.
  8. 2024 Crown Aesthetics HCP Market Tracker, September 2024.
  9. Circana MULO + Unit Sales 52 w/e 8.10.25.

INDICATION

DAXXIFY® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.

WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

IMPORTANT SAFETY INFORMATION


Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency units of DAXXIFY® are not interchangeable with preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions

The most commonly observed adverse reactions are:
Glabellar lines (≥1%): headache (6%), eyelid ptosis (2%) and facial paresis (1%).
Cervical dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (5%), muscular weakness (5%), and upper respiratory tract infection (5%).

Drug Interactions

Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations

DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch

DAXI-004726

Instagram LinkedIn

©2025 REVANCE. RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The Teoxane RHA® Collection is exclusively distributed by REVANCE. All other trademarks are the property of their respective owners. CORP-00147

CALIFORNIA PRIVACY POLICYCALIFORNIA COMPLIANCE DECLARATIONPRIVACY POLICYTERMS OF USE
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.